Keyphrases
Acute Myeloid Leukemia
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
94%
Multiple Myeloma
88%
Graft-versus-host Disease (GvHD)
57%
Granulocyte Colony-stimulating Factor (G-CSF)
55%
Hematopoietic Stem Cells
44%
Overall Survival
40%
Myelodysplastic Syndrome
34%
Tumor
34%
Bone Marrow
30%
Confidence Interval
29%
Leukemia
29%
Hematopoietic Cell Transplantation
28%
Relapsed or Refractory
27%
Relapsed or Refractory multiple Myeloma
27%
Chemotherapy
23%
Transplantation
22%
Phase II Study
21%
In Cancer
20%
T Cells
19%
Hematological Malignancies
19%
Lenalidomide
19%
Chimeric Antigen Receptor T Cells (CAR-T)
19%
Peripheral Blood
18%
Complete Remission
17%
Non-Hodgkin Lymphoma
17%
Older Adults
17%
Chronic Myeloid Leukemia
15%
High Risk
15%
Bortezomib
15%
Unrelated Donor
14%
Plerixafor
14%
Phase II Trial
14%
Progression-free Survival
14%
Carfilzomib
14%
Cancer Types
14%
Cyclophosphamide
14%
Hematopoietic Stem Cell Mobilization
13%
Myeloma
13%
Natural Killer Cells
13%
Neutrophils
12%
Clinical Trials
12%
NCCN Guidelines
12%
CD34+ Cells
12%
Autologous Transplantation
12%
Diffuse Large B-cell Lymphoma (DLBCL)
12%
Overall Response Rate
12%
Stem Cells
12%
Breast Cancer
12%
Reduced-intensity Conditioning
12%
Marrow
12%
Leukemia Patients
12%
Older Patients
11%
CD34+
11%
Cytarabine
11%
Gene Expression
11%
Hazard Ratio
11%
Allogeneic Transplantation
11%
C-X-C Chemokine Receptor Type 4 (CXCR4)
11%
Marrow Transplantation
11%
Chimeric Antigen Receptor T-cell Therapy
11%
Hematopoietic Stem Cell Transplantation
10%
Decitabine
10%
Somatic mutation
10%
Hematopoietic Cells
10%
Engraftment
10%
Placebo
10%
Acute Lymphoblastic Leukemia
10%
Lymphoma
10%
Whole Genome Sequencing
10%
Protease Inhibitors
10%
Clinical Outcomes
10%
Adverse Events
10%
Axicabtagene Ciloleucel
10%
Rituximab
9%
Event-free Survival
9%
Large B-cell Lymphoma
9%
Newly Diagnosed
9%
RNA Sequencing (RNA-seq)
9%
Stem Cell Mobilization
9%
Non-relapse Mortality
9%
Chemokine Ligand 12 (CXCL12)
9%
Cancer Genome Atlas
9%
AMD3100
9%
Cell Therapy
9%
Myeloma Cells
9%
Oncology
8%
Standard of Care
8%
Granulopoiesis
8%
Thrombocytopenia
8%
Neutropenia
8%
Relapsed or Refractory Acute Myeloid Leukemia
8%
Lymphoma Patients
8%
Multiple Myeloma Patients
8%
High Dose
8%
Stem Cell Transplantation
8%
Acute Promyelocytic Leukemia
8%
Median Overall Survival
8%
Meta-analysis
8%
Minimal Residual Disease
8%
Medicine and Dentistry
Multiple Myeloma
82%
Hematopoietic Cell
78%
Acute Myeloid Leukemia
69%
Cell Transplantation
48%
Malignant Neoplasm
45%
Overall Survival
41%
Disease
39%
Neoplasm
37%
Transplantation
37%
Myelodysplastic Syndrome
28%
Chemotherapy
27%
Granulocyte Colony Stimulating Factor
22%
Leukemia
19%
Oncology
17%
Breast Cancer
16%
Graft Versus Host Reaction
15%
Hematopoietic Stem Cell Transplantation
15%
Myeloma
14%
Acute Lymphoblastic Leukemia
14%
Progression Free Survival
14%
T Cell
14%
Adverse Event
14%
Lenalidomide
14%
Clinical Trial
14%
Non-Hodgkin Lymphoma
13%
Plerixafor
13%
Carfilzomib
13%
Chronic Graft Versus Host Disease
12%
Stem Cell Transplant
12%
Drug Megadose
12%
Hematologic Malignancy
12%
Stem Cell
12%
Chronic Myelogenous Leukemia
11%
Biological Marker
11%
Stem Cell Mobilization
11%
Arm
11%
Diffuse Large B-Cell Lymphoma
10%
Bortezomib
10%
Hazard Ratio
10%
Allograft
10%
Chimeric Antigen Receptor T-Cell Immunotherapy
10%
Cytarabine
10%
In Vitro
10%
Axicabtagene Ciloleucel
9%
Chimeric Antigen Receptor T-Cell
9%
Acute Graft Versus Host Disease
9%
Autologous Stem Cell Transplantation
9%
Progenitor Cell
9%
Large-Cell Lymphoma
9%
Cell Therapy
8%
Reduced Intensity Conditioning
8%
Hematopoiesis
8%
Conditioning
8%
Neutropenia
8%
Cyclophosphamide
8%
Immunity
8%
Autotransplantation
8%
Leukemia Cell
8%
Natural Killer Cell
8%
Acute Myelogenous Leukemia
8%
Chimeric Antigen Receptor
7%
Event Free Survival
7%
Diagnosis
7%
Tyrosine-Kinase Inhibitor
7%
Dexamethasone
7%
COVID-19
7%
Proteasome Inhibitor
7%
Cytokine
7%
B Cell
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Immunotherapy
7%
Rituximab
7%
Allogeneic Stem Cell Transplantation
7%
Acute Promyelocytic Leukemia
7%
Minimal Residual Disease
7%
Cancer
7%
Placebo
7%
Stem Cell Therapy
7%
Low Drug Dose
6%
Neutrophil
6%
Engraftment
6%
Gene Expression
6%
Somatics
6%
Metastatic Carcinoma
6%
Meta-Analysis
6%
Myeloid Leukemia
6%
Decitabine
5%
Disease Free Survival
5%
Whole Body Radiation
5%
Receptor
5%
Prostate Cancer
5%
Cancer Cell
5%
Granulocyte
5%
Acute Leukemia
5%
Infusion
5%
Cancer Types
5%
Health Care Cost
5%
Cytokine Release Syndrome
5%
High Dose Chemotherapy
5%
Mantle Cell Lymphoma
5%